CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 775 enrolled
Drug / intervention
Remifentanildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01299584
NCT01299584N/ACompleted

A Post Marketing Surveillance to Monitor the Safety of ULTIVA (Remifentanil) Adminstered in Korean Subjects According to the Prescribing Information

GlaxoSmithKline·observational·Posted Feb 18, 2011·Updated Jul 6, 2017

In Brief

An observational study evaluating Remifentanil for Analgesia. Completed, enrolled 775 participants.

Detailed Summary

This study is a post-marketing surveillance to monitor safety and efficacy of remifentanil during various surgeries and identify SAEs, adverse drug reactions, and unexpected AEs not described as precautions or warnings and to identify prognostic factors that have an effect on the AEs and to assess effectiveness of remifentanil in real clinical practices after marketing. The subjects are patients prescribed for remifentanil by the investigators at the sites based on prescription information in normal clinical practices.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnalgesia
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 18, 2011
Enrollment StartSep 1, 2005
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 15.4 years ago

Interventions

Remifentanildrug

Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.